| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 08/31/2000 | CA2362533A1 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | CA2362099A1 T cell receptor v.beta.-d.beta.-j.beta. sequence and methods for its detection |
| 08/30/2000 | EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers |
| 08/30/2000 | EP1030908A1 Genetically-modified myogenic progenitors and their use in cell and gene therapy |
| 08/30/2000 | EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity |
| 08/30/2000 | EP1030842A1 Metalloproteinase inhibitors |
| 08/30/2000 | EP0836606B1 Condensed thiazole derivatives, having 5-ht receptor affinity |
| 08/30/2000 | CN1265096A Hydrazine derivatives |
| 08/24/2000 | WO2000049015A1 Pyridine compounds and their pharmaceutical use |
| 08/24/2000 | WO2000048992A1 Acylated aminoacetonitriles as cysteine protease inhibitors |
| 08/24/2000 | WO2000048989A1 Mevinolin derivatives |
| 08/24/2000 | WO2000048623A1 Novel amide derivatives as growth hormone secretagogues |
| 08/24/2000 | WO2000048581A2 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 08/24/2000 | WO2000024362A3 Δ9 tetrahydrocannabinol (δ9 thc) solution metered dose inhalers and methods of use |
| 08/24/2000 | WO2000020025A9 Akt compositions for enhancing survival of cells |
| 08/24/2000 | WO2000015797A3 Compositions and methods for the treatment of immune related diseases |
| 08/24/2000 | CA2362538A1 Secreted proteins and polynucleotides encoding them |
| 08/24/2000 | CA2362290A1 Novel amide derivatives as growth hormone secretagogues |
| 08/23/2000 | EP1028975A1 Artemin, a novel neurotrophic factor |
| 08/23/2000 | EP1028951A1 Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors |
| 08/23/2000 | EP1028945A1 Substituted pyridine compounds as anti-inflammatory agents |
| 08/23/2000 | EP1028735A1 Therapeutic methods comprising use of a neuregulin |
| 08/23/2000 | CN1263763A Drug composition containing carboxyl oxime acide derivative |
| 08/22/2000 | CA2176973C Phenyl heterocycles as cyclooxygenase-2 inhibitors |
| 08/22/2000 | CA2143246C Imidazodiazepines |
| 08/17/2000 | WO2000047762A2 Enriched central nervous system cell populations |
| 08/17/2000 | WO2000047602A1 33 human secreted proteins |
| 08/17/2000 | WO2000047580A2 Phenyl urea and phenyl thiourea derivatives |
| 08/17/2000 | WO2000047562A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 08/17/2000 | WO2000047552A1 Tyrosine alkoxyguanidines as integrin inhibitors |
| 08/17/2000 | WO2000047238A1 Integration of transplanted neural progenitor cells into neural tissue of immature and mature dystrophic recipients |
| 08/17/2000 | WO2000047194A2 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 08/17/2000 | WO2000047149A1 Gels formed by the interaction of poly(aldehyde) with various substances |
| 08/17/2000 | CA2362372A1 Tyrosine alkoxyguanidines as integrin inhibitors |
| 08/17/2000 | CA2362272A1 Spirocyclic ketones and their use as tachykinin antagonists |
| 08/17/2000 | CA2361293A1 33 human secreted proteins |
| 08/17/2000 | CA2360233A1 Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor |
| 08/16/2000 | EP1027429A1 Jnk3 modulators and methods of use |
| 08/16/2000 | EP1027347A2 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them |
| 08/16/2000 | EP1027336A1 Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
| 08/16/2000 | EP1027335A1 Ortho-hydroxypyridinone derivatives as iron chelating and antioxidant agents |
| 08/16/2000 | EP1027325A2 Lipophilic diesters of chelating agents |
| 08/16/2000 | EP1027057A1 Treatment of female sexual dysfunction |
| 08/16/2000 | CN1263522A Compounds and methods for inhibition of expression of VCAM-1 |
| 08/16/2000 | CN1263462A Monoesters of probucol for treatment of cardiovascular and inflammatory disease |
| 08/15/2000 | US6103936 Reacting aldehyde, sulfide, sulfone, or sulfoxide with formamide in presence of acid catalyst, and optionally a dehydrating agent |
| 08/10/2000 | WO2000045801A2 Use of a nitrate vasodilator alone or in combination with capsaicin for the treatment of pain |
| 08/10/2000 | WO2000045791A2 Method for controlling liposome size |
| 08/10/2000 | WO2000024911A3 Human phospholipases |
| 08/10/2000 | WO2000010545A3 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 08/10/2000 | WO1999063936A9 Novel therapeutic agents that modulate endothelin receptors |
| 08/10/2000 | CA2361551A1 Method for controlling liposome size |
| 08/10/2000 | CA2361407A1 Pharmaceutical compositions |
| 08/09/2000 | EP1026251A2 Transgenic animals expressing human P25 |
| 08/09/2000 | EP1025099A1 Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 08/09/2000 | EP1025079A1 $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 08/09/2000 | CN1262676A 吡啶衍生物 Pyridine derivatives |
| 08/08/2000 | US6100267 Enzyme inhibitor for treatment of neurodegenerative disorders, strokes, traumatic brain injury, cataracts |
| 08/08/2000 | US6100037 Polynucleotide encoding a cyclic nucleotide phosphodiesterase having a specific amino acid sequence; diagnosis, treatment, and prevention of cancer and immune disorders; anticarcinogenic/antidiabetic/antiarthritic agents |
| 08/05/2000 | CA2267049A1 Pharmaceutical compositions |
| 08/03/2000 | WO2000044888A2 Dimethylarginine dimethylaminohydrolases |
| 08/03/2000 | WO2000044388A1 Modulation of immune response by ribavirin |
| 08/03/2000 | WO2000044377A1 Mono-acyloxy aralkyl neuromuscular relaxants |
| 08/03/2000 | WO2000044362A2 The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 08/03/2000 | WO2000044361A2 Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
| 08/03/2000 | WO2000044350A1 Transnasal transport/immunisation with highly adaptable carriers |
| 08/03/2000 | WO2000044334A2 Novel injectable muscle relaxant formulations |
| 08/03/2000 | WO2000032175A3 METHODS AND COMPOSITIONS FOR RESTORING CONFORMATIONAL STABILITY OF A PROTEIN OF THE p53 FAMILY |
| 08/03/2000 | CA2360790A1 Mono-acyloxy aralkyl neuromuscular relaxants |
| 08/03/2000 | CA2360643A1 Transnasal transport/immunisation with highly adaptable carriers |
| 08/03/2000 | CA2357735A1 Modulation of immune response by ribavirin |
| 08/02/2000 | EP1023445A1 Cadherin derived growth factor and the application thereof |
| 08/02/2000 | EP1023080A1 Ligand binding site of rage and uses thereof |
| 08/02/2000 | EP0613373B1 Risedronate delayed-release compositions |
| 08/01/2000 | US6096753 Substituted pyrimidinone and pyridone compounds and methods of use |
| 08/01/2000 | US6096748 Pyrimidine compounds useful in treating cytokine mediated diseases |
| 07/27/2000 | WO2000043495A2 33 human secreted proteins |
| 07/27/2000 | WO2000043409A2 Alpha-conotoxin peptides |
| 07/27/2000 | WO2000043387A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them |
| 07/27/2000 | WO2000043373A2 Kinase inhibitors |
| 07/27/2000 | WO2000043058A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | WO2000043020A1 Egg anti-inflammatory composition and method of treating and preventing inflammation |
| 07/27/2000 | WO2000043019A2 Egg anti-inflammatory composition and method of treating and preventing inflammation |
| 07/27/2000 | WO2000042852A1 Compounds and methods |
| 07/27/2000 | WO2000011171A3 Human rna-associated proteins |
| 07/27/2000 | WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors |
| 07/27/2000 | CA2361272A1 33 human secreted proteins |
| 07/27/2000 | CA2361138A1 Alpha-conotoxin peptides |
| 07/27/2000 | CA2359680A1 Kinase inhibitors |
| 07/27/2000 | CA2359107A1 New benzimidazole compounds for use as active therapeutic substances, process for the preparation of these compoudns and pharmaceutical compositions comprising them |
| 07/27/2000 | CA2358584A1 Method of enhancing needleless transdermal powdered drug delivery |
| 07/27/2000 | CA2355168A1 Egg anti-inflammatory composition and method of treating and preventing inflammation |
| 07/26/2000 | EP1021549A2 SENSE mRNA THERAPY |
| 07/26/2000 | EP1021461A1 Use of neuronal and lymphocytic potassium canal inhibitors for treating neurological diseases of immune origin |
| 07/26/2000 | EP1021171A1 Delayed total release gastrointestinal drug delivery system |
| 07/26/2000 | CN1260993A Exterior-applied medicine for treating soft tissue pain |
| 07/25/2000 | US6093713 A tyrosine kinase inhibitor for enhancing the function of a cholinergic neuron |
| 07/25/2000 | US6093561 Human lysophospholipase |
| 07/20/2000 | WO2000042211A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith |
| 07/20/2000 | WO2000042172A2 Human homologues of proteins regulated by circadian rhythms |